THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS
https://doi.org/10.17749/2070-4909.2017.10.2.069-074
Abstract
Among the most important aspects of the health policy are the methods for pricing of medicines, especially of innovative medicines. In many countries, the “therapeutic value” of a medicine is commonly used as a major criterion in negotiations on medicine prices. The existing tools for assessing the therapeutic value of medicines are not used in the Russian Federation. Here we propose a method for estimating the therapeutic value of innovative medicines based on the multi-criterial analysis.
About the Authors
V. K. Fedyaeva
Institute of Applied Economic Research of the Russian Presidential Academy of National Economy and Public Administration;
Research Financial Institute of the Ministry of Finance of the Russian Federation
Russian Federation
Russian Federation
Researcher at the Laboratory for Health Technology Assessment;
Senior laboratory assistant at the Health Care Finance Center,
Nastasiinsky per., 3-2, Moscow, 127006
V. V. Omelyanovskiy
Institute of Applied Economic Research of RANEPA,
Research Financial Institute of the Ministry of Finance of the Russian Federation
Russian Federation
Russian Federation
MD, Professor, Director of the Center for Technology Assessment in Health Care;
Head of the Health Care Finance Center,
Nastasiinsky per., 3-2, Moscow, 127006
N. Z. Musina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
PhD, lecturer in the Department of Pharmacology, Faculty of Pharmacy,
ul. Trubetskaya, 8-2, Moscow, 119048
G. R. Khachatryan
Institute of Applied Economic Research of the Russian Presidential Academy of National Economy and Public Administration;
Financial Scientific Research Institute at the Ministry of Finance of the Russian Federation
Russian Federation
Russian Federation
Researcher at the Laboratory for Health Technology Assessment;
junior researcher of the Center for Healthcare Funding,
Nastasiinsky per., 3-2, Moscow, 127006
O. I. Ivakhnenko
Financial Research Institute of the Ministry of finance of the Russian Federation
Russian Federation
Russian Federation
Researcher,
Nastasiinsky per., 3-2, Moscow, 127006
References
1. Soderlund N. et al. Progress toward value-based health care: lessons from 12 countries. The Boston Consulting Group, ed. Valuebased Health Care. 2012.
2. Paris V., Belloni A. Value in pharmaceutical pricing. 2013. URL: http://www.oecd-ilibrary.org/social-issues-migration-health/value-inpharmaceutical-pricing5k43jc9v6knx-en. Accessed: 25.03.2017.
3. World Health Organization. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. WHO Regional Office for Europe. 2015.
4. Omel’yanovskii V. V., Sura M. V., Sveshnikova N. D. Meditsinskie tekhnologii. Otsenka i vybor. 2011; 1: 34-41.
5. Resolution of the Government of the Russian Federation of September 15, 2015 N 979 «On Amendments to the Resolution of the Government of the Russian Federation of October 29, 2010 N 865 and on the approval of the methodology for calculating the limit selling prices for medicines on the list of vital and essential LP, with their state registration and re-registration. [Postanovlenie Pravitel’stva RF ot 15.09.2015 N 979 «O vnesenii izmenenii v postanovlenie Pravitel’stva Rossiiskoi Federatsii ot 29 oktyabrya 2010 g. N 865 i ob utverzhdenii metodiki rascheta ustanavlivaemykh proizvoditelyami LP predel’nykh otpusknykh tsen na lekarstvennye preparaty, vklyuchennye v perechen’ zhiznenno neobkhodimykh i vazhneishikh LP, pri ikh gosudarstvennoi registratsii i pereregistratsii» (in Russian)].
6. Methodical recommendations on the multicriteria analysis of decision making in the public health services of the Federal State Institution of Health Care «CECMPS» of the Ministry of Health of the Russian Federation. URL: http://rosmedex.ru/wp-content/uploads/2016/12/MR-MCDA-23.12.2016.pdf. Accessed: 16.03.2017.
7. Rebrova O. Yu. Statistical analysis of medical data. Application of the STATISTICA software package [Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA (in Russian)]. Moscow. 2002; 312 s.
Review
For citations:
Fedyaeva V.K., Omelyanovskiy V.V., Musina N.Z., Khachatryan G.R., Ivakhnenko O.I. THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2017;10(2):69-74. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.2.069-074
Views:
999
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 